89bio to Participate in the H.C. Wainwright 8th Annual MASH Investor Conference
89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on developing innovative therapies for liver and cardiometabolic diseases, has announced its participation in the H.C. Wainwright 8th Annual MASH Investor Conference. The company's management will take part in a fireside chat and one-on-one investor meetings on Monday, October 7, 2024, at 11:30 AM ET.
Investors and interested parties can access the webcast of the presentation through the investor section of 89bio's website. A replay of the webcast will be available for approximately 30 days after the conference. This event provides an opportunity for 89bio to showcase its progress and engage with potential investors in the biopharmaceutical sector.
89bio, Inc. (Nasdaq: ETNB), una società biofarmaceutica in fase clinica, focalizzata nello sviluppo di terapie innovative per malattie epatiche e cardiometaboliche, ha annunciato la sua partecipazione alla 8ª Conferenza Annuale degli Investitori MASH di H.C. Wainwright. La direzione dell'azienda parteciperà a una chiacchierata informale e a incontri individuali con gli investitori lunedì 7 ottobre 2024, alle 11:30 AM ET.
Gli investitori e le parti interessate possono accedere alla trasmissione in diretta della presentazione attraverso la sezione investitori del sito web di 89bio. Una registrazione della trasmissione sarà disponibile per circa 30 giorni dopo la conferenza. Questo evento offre a 89bio l'opportunità di mostrare i suoi progressi e interagire con potenziali investitori nel settore biofarmaceutico.
89bio, Inc. (Nasdaq: ETNB), una compañía biofarmacéutica en etapa clínica centrada en el desarrollo de terapias innovadoras para enfermedades hepáticas y cardiometabólicas, ha anunciado su participación en la 8ª Conferencia Anual de Inversores MASH de H.C. Wainwright. La dirección de la empresa participará en una charla informal y en reuniones individuales con inversores el lunes 7 de octubre de 2024, a las 11:30 AM ET.
Los inversores y partes interesadas pueden acceder a la transmisión web de la presentación a través de la sección de inversores en el sitio web de 89bio. Una repetición de la transmisión estará disponible durante aproximadamente 30 días después de la conferencia. Este evento brinda a 89bio la oportunidad de mostrar sus avances e interactuar con posibles inversores en el sector biofarmacéutico.
89bio, Inc. (Nasdaq: ETNB)는 간 및 심혈관 대사 질환을 위한 혁신적인 치료법 개발에 중점을 둔 임상 단계의 생명공학 회사로, H.C. Wainwright 제8회 연례 MASH 투자자 회의에 참여한다고 발표했습니다. 회사의 경영진은 2024년 10월 7일 월요일, 오후 11:30 ET에 파이어사이드 채팅과 일대일 투자자 회의에 참석합니다.
투자자와 관심 있는 분들은 89bio 웹사이트의 투자자 섹션을 통해 발표의 웹캐스트에 접속할 수 있습니다. 회의 후 약 30일 동안 재생이 가능할 것입니다. 이 행사는 89bio가 자신의 발전을 보여주고 생명공학 부문의 잠재적 투자자들과 교류할 수 있는 기회를 제공합니다.
89bio, Inc. (Nasdaq: ETNB), une entreprise biopharmaceutique en phase clinique axée sur le développement de thérapies innovantes pour les maladies hépatiques et cardiométaboliques, a annoncé sa participation à la 8ème Conférence Annuelle des Investisseurs MASH de H.C. Wainwright. La direction de l'entreprise participera à une discussion informelle et à des réunions individuelles avec les investisseurs le lundi 7 octobre 2024, à 11h30 ET.
Les investisseurs et les parties intéressées peuvent accéder au webinaire de la présentation via la section investisseurs du site Web de 89bio. Un enregistrement du webinaire sera disponible pendant environ 30 jours après la conférence. Cet événement offre à 89bio l'occasion de présenter ses progrès et d'interagir avec de potentiels investisseurs dans le secteur biopharmaceutique.
89bio, Inc. (Nasdaq: ETNB), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf die Entwicklung innovativer Therapien für Leber- und kardiometabolische Erkrankungen konzentriert, hat seine Teilnahme an der 8. jährlichen MASH-Investorenkonferenz von H.C. Wainwright angekündigt. Die Unternehmensführung wird an einem informellen Gespräch und Einzelgesprächen mit Investoren am Montag, den 7. Oktober 2024, um 11:30 Uhr ET teilnehmen.
Investoren und Interessierte können über den Investorenbereich der Website von 89bio auf das Webcast der Präsentation zugreifen. Eine Wiederholung des Webcasts wird etwa 30 Tage nach der Konferenz verfügbar sein. Diese Veranstaltung bietet 89bio die Möglichkeit, seine Fortschritte zu präsentieren und mit potenziellen Investoren im biopharmazeutischen Sektor in Kontakt zu treten.
- None.
- None.
SAN FRANCISCO, Sept. 30, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (the “Company” or “89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that the Company’s Management will participate in a fireside chat and one-on-one investor meetings at the H.C. Wainwright 8th Annual MASH Investor Conference on Monday, October 7, 2024 at 11:30 AM ET.
The webcast of the presentation will be accessible in the investor section of 89bio’s website. A replay of the webcast will be available for approximately 30 days following the conference.
About 89bio
89bio is a clinical-stage biopharmaceutical company dedicated to the development of best-in-class therapies for patients with liver and cardiometabolic diseases who lack optimal treatment options. The company is in Phase 3 studies for its lead candidate, pegozafermin, for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and severe hypertriglyceridemia (SHTG). Pegozafermin is a specifically engineered, potentially best-in-class fibroblast growth factor 21 (FGF21) analog with unique glycoPEGylated technology that optimizes biological activity through an extended half-life. The company is headquartered in San Francisco. For more information, visit www.89bio.com or follow the company on LinkedIn.
Investor Contact:
Annie Chang
89bio, Inc.
investors@89bio.com
PJ Kelleher
LifeSci Advisors, LLC
617-430-7579
pkelleher@lifesciadvisors.com
Media Contact:
Sheryl Seapy
Real Chemistry
sseapy@realchemistry.com
FAQ
When is 89bio (ETNB) participating in the H.C. Wainwright MASH Investor Conference?
What type of company is 89bio (ETNB)?
How can investors access 89bio's (ETNB) presentation at the H.C. Wainwright conference?
How long will the replay of 89bio's (ETNB) presentation be available?
